Driven by viral hype from wellness influencers, celebrities and biohacking circles, synthetic peptides have exploded in popularity as miracle substances promising everything from wrinkle-free skin and deeper sleep to faster muscle repair and extended lifespan. But this booming, unregulated market is now under formal scrutiny in the United States, as a Food and Drug Administration (FDA) advisory panel convenes this week to weigh whether seven of the most in-demand peptides should be cleared for pharmacy compounding – the custom formulation of drugs by pharmacists or specialized outsourcing facilities.
The review comes as public interest in peptides has skyrocketed, even as leading medical researchers and safety advocates sound the alarm over a total lack of rigorous clinical evidence confirming the substances are either safe or effective for widespread use. “There’s just not enough clinical data to say whether these peptides are safe and effective,” Alexander Weber, chief of sports medicine at the University of Southern California and an orthopedic surgeon, told AFP. He added that peptides have become a regular topic of conversation in his daily patient consultations, a sign of how deeply mainstream the unproven trend has become.
The seven peptides up for review – including popular compounds BPC-157, TB-500 and Semax – were already restricted from compounding by the prior Biden administration, primarily due to the absence of gold-standard human clinical trial data. Despite the restrictions, use of the substances has persisted widely: consumers can currently purchase the compounds online from chemical suppliers marketed strictly “for lab use only,” a loophole that enables off-label consumer use.
Supporters of loosening restrictions, including wellness influencers, peptide industry advocates and even US Health Secretary nominee Robert F. Kennedy Jr. (who has publicly stated he uses peptides to treat personal injuries), argue that the current restrictions have created an unregulated gray market flooded with low-quality products from unvetted overseas suppliers. “With the gray market you have no idea if you’re getting a good product,” Kennedy told podcast host Joe Rogan in a recent interview, adding that much of the available product on the market is substandard. However, critics have accused Kennedy of stacking the FDA advisory panel with individuals who hold deep financial and professional ties to the peptide industry, given his personal and political alignment with pro-peptide interests.
“In ordinary circumstances, I would say that these products are dead,” said Peter Lurie, president of the Center for Science in the Public Interest and a former FDA official. “But given the way that the committee is stacked, I don’t have that confidence at all.”
Peptides are naturally occurring short chains of amino acids, the fundamental building blocks of proteins, that act as signaling molecules to regulate core physiological processes ranging from tissue repair to metabolism. Well-known, widely studied peptides include insulin, a life-saver for people with diabetes, and GLP-1 weight loss and diabetes treatments such as Ozempic – both of which have passed extensive FDA testing for safety and efficacy. But the injectable synthetic peptides promoted by wellness influencers have never undergone the large-scale clinical trials the FDA requires to confirm safety and effectiveness.
FDA career scientists have already published formal analyses warning that even amid the cultural hype, existing evidence is insufficient to justify rolling back restrictions. Their concerns align with a May joint white paper from nonprofits ECRI and the Institute for Safe Medication Practices (ISMP), which called the gap between the fast-growing commercial market and limited clinical research “an alarming safety concern.” “The commercial market has grown faster than the clinical evidence base, and the absence of adequate clinical evidence for use in humans is an alarming safety concern,” the paper read. Rita Jew, ISMP president, told AFP there is no new data that would justify approving the seven peptides for compounding.
Not all medical providers oppose easing restrictions, however. Ed Lee, an Orlando-based endocrinologist and co-founder of the Clinical Peptides Society, has led a petition drive called “Save Peptides” that has collected nearly 10,000 signatures urging federal lawmakers to loosen peptide regulations. Lee is particularly optimistic about the tissue repair benefits touted for BPC-157, and argues that public demand for the compounds is already so high that regulators cannot reverse the trend. “I don’t know how they’re going to put the genie back in the bottle,” he said.
But critics push back on the argument that consumer demand alone is enough to justify regulatory approval, given the extremely limited scientific backing. “If at the end of the day these products are approved, I see nothing good coming out of it,” Lurie said. Weber acknowledged that many of his patients report positive anecdotal results from peptide use, but warned that anecdotal experiences are not a substitute for rigorous research. Patients who pay out of pocket for the unproven treatments are often biased to believe they work, he noted: “If you’re paying for something, you want it to work.”